Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 3/20 | 0.45 |
| ▸ | CCNH | P51946 | 3/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.42 |
| ▸ | TCF7L2 | Q9NQB0 | 3/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144342 | 0.95 | BACE1 (0.46) | BACE1CDK7CCNHCTNNB1TCF7L2 | |
| SCHEMBL4147825 | 0.93 | CDK7 (0.46) | BACE1CDK7CCNHCTNNB1TCF7L2 | |
| SCHEMBL28812000 | 0.90 | BACE1 (0.44) | BACE1CDK7CCNHCTNNB1TCF7L2 | |
| SCHEMBL4142406 | 0.90 | BACE1 (0.49) | BACE1CDK7CCNHCTNNB1TCF7L2 | |
| SCHEMBL4134753 | 0.89 | CDK7 (0.45) | BACE1CDK7CCNHCTNNB1TCF7L2 | |
| SCHEMBL4142333 | 0.88 | ACP1 (0.52) | BACE1CDK7CCNHCTNNB1TCF7L2 | |
| SCHEMBL4132187 | 0.88 | BACE1 (0.46) | BACE1CDK7CCNHCTNNB1TCF7L2 | |
| SCHEMBL4132202 | 0.87 | BACE1 (0.47) | BACE1CDK7CCNHCTNNB1TCF7L2 | |
| SCHEMBL4145826 | 0.87 | BACE1 (0.43) | BACE1CDK7CCNHCTNNB1TCF7L2 | |
| SCHEMBL4144373 | 0.87 | CDK7 (0.44) | BACE1CDK7CCNHCTNNB1TCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | claimed |
| EP-2134695-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | Exelixis, Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | claimed |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | UNIVERSITY OF SOUTH ALABAMA (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | UNIVERSITY OF SOUTH ALABAMA (US) | 2014-10-16 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS PATENT COMPANY LLC (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS PATENT COMPANY LLC (US) | 2012-09-20 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238570-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | SHH, GLI1, SMO | BACE1 1857/4885CDK7 886/4885CCNH 888/4885 |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | SHH, GLI1, SMO | BACE1 2093/4885CDK7 870/4885CCNH 925/4885 |
| US-20140309184-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OVARIAN CANCER | TP53, ANXA5, VHL | BACE1 4340/4885CDK7 2285/4885CCNH 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.